The ongoing ARCHER 1009 study, a phase III, multicenter, double-blinded trial comparing dacomitinib to erlotinib in pretreatred NSCLC will clarify whether new generation EGFR-TKIs are superior to first-generation agents particularly in the KRAS wild-type population [29]. Here, KRAS is linked to non-small cell lung carcinoma.